关注
Toni Choueiri
Toni Choueiri
Dana-Farber Cancer Institute
在 dfci.harvard.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
Nivolumab versus everolimus in advanced renal-cell carcinoma
RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ...
New England Journal of Medicine 373 (19), 1803-1813, 2015
60332015
Post-acute COVID-19 syndrome
A Nalbandian, K Sehgal, A Gupta, MV Madhavan, C McGroder, ...
Nature medicine 27 (4), 601-615, 2021
45982021
The immune landscape of cancer
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
45122018
Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma
RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ...
New England Journal of Medicine 378 (14), 1277-1290, 2018
40852018
Comprehensive molecular characterization of clear cell renal cell carcinoma
Cancer Genome Atlas Research Network Analysis working group: Baylor College ...
Nature 499 (7456), 43-49, 2013
3629*2013
Pembrolizumab as second-line therapy for advanced urothelial carcinoma
J Bellmunt, R De Wit, DJ Vaughn, Y Fradet, JL Lee, L Fong, NJ Vogelzang, ...
New England Journal of Medicine 376 (11), 1015-1026, 2017
32272017
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large …
DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ...
Journal of clinical oncology 27 (34), 5794-5799, 2009
22832009
Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ...
New England Journal of Medicine 380 (12), 1103-1115, 2019
22692019
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ...
New England Journal of Medicine 369 (8), 722-731, 2013
20982013
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
18562020
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma
R Motzer, B Alekseev, SY Rha, C Porta, M Eto, T Powles, V Grünwald, ...
New England Journal of Medicine 384 (14), 1289-1300, 2021
12692021
Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma
TK Choueiri, T Powles, M Burotto, B Escudier, MT Bourlon, B Zurawski, ...
New England Journal of Medicine 384 (9), 829-841, 2021
12682021
Cabozantinib versus everolimus in advanced renal-cell carcinoma
TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ...
New England Journal of Medicine 373 (19), 1814-1823, 2015
12672015
Systemic therapy for metastatic renal-cell carcinoma
TK Choueiri, RJ Motzer
New England Journal of Medicine 376 (4), 354-366, 2017
11422017
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ...
Nature medicine 24 (6), 749-757, 2018
10452018
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ...
The lancet oncology 17 (7), 917-927, 2016
10422016
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
DYC Heng, W Xie, MM Regan, LC Harshman, GA Bjarnason, ...
The lancet oncology 14 (2), 141-148, 2013
10402013
Marital status and survival in patients with cancer
AA Aizer, MH Chen, EP McCarthy, ML Mendu, S Koo, TJ Wilhite, ...
Journal of clinical oncology 31 (31), 3869-3876, 2013
10302013
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
D Miao, CA Margolis, W Gao, MH Voss, W Li, DJ Martini, C Norton, ...
Science 359 (6377), 801-806, 2018
10212018
Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets
PK Brastianos, SL Carter, S Santagata, DP Cahill, A Taylor-Weiner, ...
Cancer discovery 5 (11), 1164-1177, 2015
10122015
系统目前无法执行此操作,请稍后再试。
文章 1–20